Radiology
-
Randomized Controlled Trial
Peripheral arteries: treatment with antibodies of platelet receptors and reteplase for thrombolysis--APART trial.
To prospectively compare the safety and efficacy of combination therapy with the glycoprotein IIb/IIIa antagonist abciximab plus the third-generation thrombolytic agent reteplase versus those of therapy with the standard thrombolytic agent urokinase plus abciximab. ⋯ The proposed regimen resulted in only a limited number of major complications, and the low amputation rate in both groups may be attributed to abciximab.
-
Comparative Study
Amyotrophic lateral sclerosis: diffusion-tensor and chemical shift MR imaging at 3.0 T.
To prospectively determine whether diffusion-tensor magnetic resonance (MR) imaging in conjunction with two-dimensional chemical shift imaging can assist in identifying upper motor neuron involvement and whether disease severity and duration can be predicted based on imaging parameters in patients with amyotrophic lateral sclerosis (ALS). ⋯ Diffusion-tensor and two-dimensional chemical shift MR imaging spectroscopy can be used to identify upper motor neuron involvement and predict disease duration in patients with ALS.
-
Comparative Study
Term neonate prognoses after perinatal asphyxia: contributions of MR imaging, MR spectroscopy, relaxation times, and apparent diffusion coefficients.
To retrospectively evaluate magnetic resonance (MR) imaging, hydrogen 1 (1H) MR spectroscopy, apparent diffusion coefficient (ADC), T1, and T2 measurements for prediction of late neurologic outcome in term neonates after severe perinatal asphyxia. ⋯ Conventional MR imaging findings, spectroscopically measured absolute NAA and choline concentrations, and ADCs are complementary tools for predicting the individual outcomes of severely asphyxiated term neonates.
-
To retrospectively characterize the extent and nature of financial relationships with industry that are disclosed in the abstracts of scientific papers presented at the 2003 Radiological Society of North America (RSNA) Annual Meeting and to retrospectively assess whether the presence of relationships between researchers and industry was associated with a discussion on the use of products or devices that are not yet approved by the U.S. Food and Drug Administration (FDA). ⋯ RSNA abstracts in which authors disclosed corporate financial relationships were twice as likely as those without such disclosures to discuss non-FDA-approved use of a commercial product. This raises the possibility that corporate relationships may influence radiology research.